BLPH | Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences

WARREN, N.J., Oct.29, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc.(Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that data from its Phase 2 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of fibrotic Interstitial Lung Disease patients at risk […]

BLPH | Bellerophon Therapeutics (NASDAQ:BLPH) Stock Rating Lowered by Zacks Investment Research

Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company.It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases.The […]The Olympia Report